AQR Capital Management
AVBP icon

AQR Capital Management’s ArriVent BioPharma AVBP Stock Holding History

AQR Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$367K Buy
15,923
+4,448
+39% +$100K ﹤0.01% 3305
2025
Q4 		$231K Sell
11,475
-348
-3% -$7.24K ﹤0.01% 3296
2025
Q3 		$218K Sell
11,823
-2,513
-18% -$49.4K ﹤0.01% 3223
2025
Q2 		$312K Buy
+14,336
New +$298K ﹤0.01% 2856
2025
Q1 		– Sell
-8,868
Closed -$236K – 3209
2024
Q4 		$236K Buy
8,868
+211
+2% +$6.06K ﹤0.01% 2607
2024
Q3 		$203K Buy
+8,657
New +$197K ﹤0.01% 2562

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AQR Capital Management's AVBP Position: Q1 2026 in Review

AQR Capital Management increased its ArriVent BioPharma (AVBP) stake by 39% in Q1 2026, buying an estimated $100K and bringing the position to 15,923 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #3305.

AQR Capital Management first reported a position in AVBP in Q3 2024 and has held it in 6 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • AQR Capital Management held 15,923 shares of ArriVent BioPharma worth $367K as of Q1 2026.
  • AQR Capital Management bought 4,448 ArriVent BioPharma shares in Q1 2026, an estimated $100K.
  • ArriVent BioPharma made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3305 holding.
  • AQR Capital Management first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 6 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.